Department of Surgery, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Medicina (Kaunas). 2021 Jul 28;57(8):767. doi: 10.3390/medicina57080767.
: Development of hepatitis-B is considered a serious complication after liver transplantation. HBV de novo infection is a rather rare phenomenon, however it deserves attention in the era of donor organ shortage. The aim of the present analysis was to examine its course in liver transplant patients. : Prevalence of de novo HBV-infections was extracted from our local transplant data base. Analysis focused on the moment of HBV-detection and on the long-term follow-up in terms of biochemical and histological changes over 30 years. : 46 patients were identified with the diagnosis of de novo hepatitis B. Median time from liver transplantation to diagnosis was 397 days (7-5505). 39 patients received antiviral therapy. No fibrosis progression could be detected, whereas the grade of inflammation significantly lessened from the moment of HBV detection to the end of histological follow-up over a median of 4344 days (range 123-9490). Patients with a poor virological control demonstrated a significantly poorer overall survival. : De novo hepatitis B in liver transplant patients is a condition that can be controlled very well without significant fibrosis progression or graft loss if recognized on time within a regular transplant follow-up schedule.
乙型肝炎的发展被认为是肝移植后的严重并发症。HBV 新发感染是一种相当罕见的现象，但在供体器官短缺的时代值得关注。本分析的目的是检查其在肝移植患者中的病程。：从我们的本地移植数据库中提取了新发性乙型肝炎感染的患病率。分析集中在乙型肝炎检测的时刻，以及在 30 年的时间内从生化和组织学变化的长期随访方面。：46 例患者被诊断为新发乙型肝炎。从肝移植到诊断的中位时间为 397 天（7-5505）。39 例患者接受了抗病毒治疗。未检测到纤维化进展，而炎症程度从乙型肝炎检测到组织学随访结束的中位数为 4344 天（范围 123-9490）显著降低。病毒学控制不佳的患者总生存率明显较差。：如果在定期移植随访计划中及时发现，肝移植患者的新发乙型肝炎是一种可以很好控制的疾病，不会导致明显的纤维化进展或移植物丢失。
